Perspective Therapeutics Inc (CATX)

[stealthways]

AF takes liberties with the lung cancer results to drop the stock price
AF claims in his report that "Few investors are reading the actual study involving Cesium-131 published in the medical journal Brachytherapy. If they read the study -- and I did -- you'd see IsoRay is lazy with the facts."
Lets see who is lazy with the facts:
1. AF writes "96% of lung cancer patients demonstrated "local control" (meaning control of tumor in the lung) following surgery plus treatment with Cesium-131. But two other groups of lung cancer patients in the Brachytherapy study who had either surgery alone or a different form of radiation therapy demonstrated statistically equivalent rates of local control. The study authors note there were no differences in local control rates between the groups of lung cancer patients."

The facts based on the link of the study results in the PR are " Cs-131 was used with WRs that the surgeons deemed high risk and LC was 96.2% in WR+CS131 group versus 92.2% with WR group that did not include high risk patients". These results are outstanding for the WR+CS131 group considering it had high risk patients.

by r_taparia